Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA: A Cancer J Clinic. 2023;73(1):17–48. https://doi.org/10.3322/caac.21763.

Article  Google Scholar 

Lord S, Bahlmann K, O’Connell D, et al. De novo and recurrent metastatic breast cancer – a systematic review of population-level changes in survival since 1995. eClinicalMedicine. 2022;44 https://doi.org/10.1016/j.eclinm.2022.101282.

Jain DK, Kaushal M, Mathur RK. Epidemiology, acceptability, awareness & management of breast cancer at tertiary centre in India. Breast. 2013;22:S40–0.

Google Scholar 

Halsted CP, Benson JR, Jatoi I. A historical account of breast cancer surgery: beware of local recurrence but be not radical. Future Oncol. 2014;10(9):1649–57.

Article  CAS  PubMed  Google Scholar 

Fisher B, Ravdin RG, Ausman RK, Slack NH, Moore GE, Noer RJ. Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigation. Ann Surg. 1968;168(3):337.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8–10. https://doi.org/10.1200/JCO.1995.13.1.8.

Article  CAS  PubMed  Google Scholar 

Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019;393(10185):2051–8. https://doi.org/10.1016/S0140-6736(18)32487-5.

Article  PubMed  Google Scholar 

Gomez DR, Tang C, Zhang J, et al. Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol. 2019;37(18):1558–65. https://doi.org/10.1200/JCO.19.00201.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ost P, Reynders D, Decaestecker K, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol. 2018;36(5):446–53. https://doi.org/10.1200/JCO.2017.75.4853.

Article  CAS  PubMed  Google Scholar 

Iyengar P, Wardak Z, Gerber DE, et al. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol. 2018;4(1):e173501. https://doi.org/10.1001/jamaoncol.2017.3501.

Article  PubMed  Google Scholar 

Ruers T, Van Coevorden F, Punt CJA, et al. Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial. J Natl Cancer Inst. 2017;109(9) https://doi.org/10.1093/jnci/djx015.

Dingemans AMC, Hendriks LEL, Berghmans T, et al. Definition of synchronous oligometastatic non–small cell lung cancer—a consensus report. J Thoracic Oncol. 2019;14(12):2109–19. https://doi.org/10.1016/j.jtho.2019.07.025.

Article  Google Scholar 

Steenbruggen TG, Schaapveld M, Horlings HM, et al. Characterization of oligometastatic disease in a real-world nationwide cohort of 3447 patients with de novo metastatic breast cancer. JNCI Cancer Spectr. 2021;5(3) https://doi.org/10.1093/jncics/pkab010.

Chalkidou A, Macmillan T, Grzeda MT, et al. Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study. Lancet Oncol. 2021;22(1):98–106. https://doi.org/10.1016/S1470-2045(20)30537-4.

Article  PubMed  Google Scholar 

Vassantachart AK, Lock D, Han HR, Ye JC. Stereotactic body radiation in breast cancer — definitive, oligometastatic, and beyond. Curr Breast Cancer Rep. 2022;14(3):53–64. https://doi.org/10.1007/s12609-022-00447-1.

Article  Google Scholar 

Gianni L, Romieu GH, Lichinitser M, et al. AVEREL: a randomized phase III trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. JCO. 2013;31(14):1719–25. https://doi.org/10.1200/JCO.2012.44.7912.

Article  CAS  Google Scholar 

Hurvitz SA, Dirix L, Kocsis J, et al. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2013;31(9):1157–63.

Article  CAS  PubMed  Google Scholar 

Albain KS, Nag SM, Calderillo-Ruiz G, et al. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol. 2008;26(24):3950–7.

Article  PubMed  Google Scholar 

Lievens Y, Guckenberger M, Gomez D, et al. Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document. Radiother Oncol. 2020;148:157–66. https://doi.org/10.1016/j.radonc.2020.04.003.

Article  PubMed  Google Scholar 

Guckenberger M, Lievens Y, Bouma AB, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020;21(1):e18–28. https://doi.org/10.1016/S1470-2045(19)30718-1.

Article  PubMed  Google Scholar 

AlSendi M, O’Reilly D, Zeidan YH, Kelly CM. Oligometastatic breast cancer: are we there yet? Int J Cancer. 2021;149(8):1520–8. https://doi.org/10.1002/ijc.33693.

Article  CAS  PubMed  Google Scholar 

Perez-Garcia J, Cortez P, Gion M, Cortes J. Can we cure oligometastatic disease? A practical point of view. Curr Opin Oncol. 2020;32(6):568–74. https://doi.org/10.1097/CCO.0000000000000684.

Article  PubMed  Google Scholar 

Cheung P. Stereotactic body radiotherapy for oligoprogressive cancer. The British J Radiol. 2016;89(1066):20160251.

Article  Google Scholar 

Patel PH, Palma D, McDonald F, Tree AC. The dandelion dilemma revisited for oligoprogression: treat the whole lawn or weed selectively? Clin Oncol. 2019;31(12):824–33.

Article  CAS  Google Scholar 

Ramadan S, Quan K, Schnarr K, et al. Impact of stereotactic body radiotherapy (SBRT) in oligoprogressive metastatic disease. Acta Oncol. 2022;61(6):705–13. https://doi.org/10.1080/0284186X.2022.2063067.

Article  CAS  PubMed  Google Scholar 

Nicosia L, Figlia V, Ricottone N, et al. Stereotactic body radiotherapy (SBRT) and concomitant systemic therapy in oligoprogressive breast cancer patients. Clin Exp Metastasis. 2022;39(4):581–8. https://doi.org/10.1007/s10585-022-10167-6.

Article  PubMed  Google Scholar 

Chikarmane SA, Tirumani SH, Howard SA, Jagannathan JP, DiPiro PJ. Metastatic patterns of breast cancer subtypes: what radiologists should know in the era of personalized cancer medicine. Clin Radiol. 2015;70(1):1–10. https://doi.org/10.1016/j.crad.2014.08.015.

Article  CAS  PubMed  Google Scholar 

Maki DD, Grossman RI. Patterns of disease spread in metastatic breast carcinoma: influence of estrogen and progesterone receptor status. Am J Neuroradiol. 2000;21(6):1064–6.

CAS  PubMed  PubMed Central  Google Scholar 

Vietti Violi N, Hajri R, Haefliger L, Nicod-Lalonde M, Villard N, Dromain C. Imaging of oligometastatic disease. Cancers (Basel). 2022;14(6) https://doi.org/10.3390/cancers14061427.

Liu B, Gao S, Li S. A comprehensive comparison of CT, MRI, positron emission tomography or positron emission tomography/CT, and diffusion weighted imaging-MRI for detecting the lymph nodes metastases in patients with cervical cancer: a meta-analysis based on 67 studies. Gynecol Obstetric Invest. 2017;82(3):209–22.

Article  CAS  Google Scholar 

O’Sullivan GJ, Carty FL, Cronin CG. Imaging of bone metastasis: an update. World J Radiol. 2015;7(8):202.

Article  PubMed  PubMed Central  Google Scholar 

Pirasteh A, Lovrec P, Pedrosa I. Imaging and its impact on defining the oligometastatic state. Semin Radiat Oncol. 2021;31(3):186–99. https://doi.org/10.1016/j.semradonc.2021.03.006.

Article  PubMed  Google Scholar 

Sun Z, Yi YL, Liu Y, Xiong JP, He CZ. Comparison of whole-body PET/PET-CT and conventional imaging procedures for distant metastasis staging in patients with breast cancer: a meta-analysis. Eur J Gynaecol Oncol. 2015;36(6):672–6.

PubMed  Google Scholar 

Hong S, Li J, Wang S. 18FDG PET-CT for diagnosis of distant metastases in breast cancer patients. A meta-analysis. Surg Oncol. 2013;22(2):139–43.

Article  PubMed  Google Scholar 

Pestalozzi BC. Not Available. Oncol Res Treat. 2014;37(Suppl 5):1–332. https://doi.org/10.1159/000368945.

Article  Google Scholar 

Dashevsky BZ, Goldman DA, Parsons M, et al. Appearance of untreated bone metastases from breast cancer on FDG PET/CT: importance of histologic subtype. Eur J Nuclear Med Mol Imaging. 2015;42:1666–73.

Article  Google Scholar 

Hogan MP, Goldman DA, Dashevsky B, et al. Comparison of 18F-FDG PET/CT for systemic staging of newly diagnosed invasive lobular carcinoma versus invasive ductal carcinoma. J Nuclear Med. 2015;56(11):1674–80.

Article  CAS  Google Scholar 

Dayes IS, Metser U, Hodgson N, et al. Impact of 18F-labeled fluorodeoxyglucose positron emission tomography-computed tomography versus conventional staging in patients with locally advanced breast cancer. JCO. 2023;41(23):3909–16. https://doi.org/10.1200/JCO.23.00249.

Article  CAS  Google Scholar 

van Kruchten M, de Vries EG, Glaudemans AW, et al. Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer. Cancer Discov. 2015;5(1):72–81.

Article  PubMed  Google Scholar 

Evangelista L, Vittoria Dieci M, Guarneri V, Franco CP. 18F-fluoroestradiol positron emission tomography in breast cancer patients: systematic review of the literature & meta-analysis. Curr Radiopharmaceut. 2016;9(3):244–57.

Article  CAS  Google Scholar 

Kurland BF, Peterson LM, Lee JH, et al. Estrogen receptor binding (18F-FES PET) and glycolytic activity (18F-FDG PET) predict progression-free survival on endocrine therapy in patients with ER+ breast cancer. Clin Cancer Res. 2017;23(2):407–15.

Article  CAS  PubMed